EUVIMEDEUVIMED entdecken
Übersichtsarbeit

EBV‐Positive Diffuse Large B‐Cell Lymphoma (DLBCL): An Assessment and a Roadmap

Pierluigi Porcu, Rebecca Masel, Nicholas Kendsersky, Cara Noel, Christoph Weigel, Alan S Khoo, Robert A Baiocchi iD

Journal of Medical Virology · 2025-12 · 97 (12)

DOI: 10.1002/jmv.70722 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medical Virology, online erschienen am 27.11.2025. Verfasst von Pierluigi Porcu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and BMT, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections, Herpesvirus 4, Human. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 129 Literaturangaben. Gefördert von: Cara Noel was supported, in part, by the STRIVE T35 Research Program, T35AI179601..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B‐cell Lymphoma (DLBCL) is the most common lymphoma subtype worldwide. The Epstein Barr Virus (EBV) is a human DNA virus associated with a spectrum of human malignancies. EBV is detected in 5% to 15% of DLBCL tumors with no history of immunosuppression. Early reports of EBV‐positive DLBCL suggested distinct clinical presentation, unique tumor microenvironment (TME), and inferior survival compared to EBV‐negative DLBCL. A better definition of EBV‐positive cases treated with modern chemo‐immunotherapy has recently improved our understanding of this entity. Recent studies have provided initial insights into the distinct mutational landscape and immune microenvironment of EBV‐positive DLBCL and identified EBV as an independent prognostic biomarker in DLBCL. Despite these advances, fundamental questions remain. We provide an overview of emerging clinical and molecular aspects of EBV‐positive DLBCL and discuss recent efforts to develop EBV‐targeting therapies. We also discuss key research questions in EBV‐positive DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHumansTumor MicroenvironmentPrognosisImmunotherapy

Stichwörter der Autor:innen

DLBCLEBVglobalimmunocompetentimmunocompromisedimmunotherapylatencylyticmicroenvironment

Autor:innen und Institutionen

  • Division of Hematology and BMT, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
  • Department of Medical Oncology, Sindey Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Oregon Health Sciences University, Portland, Oregon, USA.
  • Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.

ORCID-Profile: Robert A Baiocchi

Förderung

  • Cara Noel was supported, in part, by the STRIVE T35 Research Program, T35AI179601.

Zitieren

APA

Porcu, P., Masel, R., Kendsersky, N., Noel, C., Weigel, C., Khoo, A. S., & Baiocchi, R. A. (2025). EBV‐Positive Diffuse Large B‐Cell Lymphoma (DLBCL): An Assessment and a Roadmap. Journal of Medical Virology, 97(12). https://doi.org/10.1002/jmv.70722

Vancouver

Porcu P, Masel R, Kendsersky N, Noel C, Weigel C, Khoo AS, et al. EBV‐Positive Diffuse Large B‐Cell Lymphoma (DLBCL): An Assessment and a Roadmap. Journal of Medical Virology. 2025;97(12). doi:10.1002/jmv.70722

BibTeX
@article{Porcu2025,
  author = {Porcu, Pierluigi and Masel, Rebecca and Kendsersky, Nicholas and Noel, Cara and Weigel, Christoph and Khoo, Alan S and Baiocchi, Robert A},
  title = {EBV‐Positive Diffuse Large B‐Cell Lymphoma (DLBCL): An Assessment and a Roadmap},
  journal = {Journal of Medical Virology},
  year = {2025},
  volume = {97},
  number = {12},
  doi = {10.1002/jmv.70722}
}
Kostenlos starten →